JP2019521098A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521098A5 JP2019521098A5 JP2018562357A JP2018562357A JP2019521098A5 JP 2019521098 A5 JP2019521098 A5 JP 2019521098A5 JP 2018562357 A JP2018562357 A JP 2018562357A JP 2018562357 A JP2018562357 A JP 2018562357A JP 2019521098 A5 JP2019521098 A5 JP 2019521098A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- binding fragment
- complementarity determining
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022130091A JP2022159476A (ja) | 2016-06-10 | 2022-08-17 | 抗ｇｉｔｒ抗体およびその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662348353P | 2016-06-10 | 2016-06-10 | |
| US62/348,353 | 2016-06-10 | ||
| US201662432023P | 2016-12-09 | 2016-12-09 | |
| US62/432,023 | 2016-12-09 | ||
| US201762500312P | 2017-05-02 | 2017-05-02 | |
| US62/500,312 | 2017-05-02 | ||
| PCT/US2017/036818 WO2017214548A1 (en) | 2016-06-10 | 2017-06-09 | Anti-gitr antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130091A Division JP2022159476A (ja) | 2016-06-10 | 2022-08-17 | 抗ｇｉｔｒ抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019521098A JP2019521098A (ja) | 2019-07-25 |
| JP2019521098A5 true JP2019521098A5 (https=) | 2020-07-27 |
| JP7162535B2 JP7162535B2 (ja) | 2022-10-28 |
Family
ID=59078260
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018562357A Active JP7162535B2 (ja) | 2016-06-10 | 2017-06-09 | 抗ｇｉｔｒ抗体およびその使用 |
| JP2022130091A Pending JP2022159476A (ja) | 2016-06-10 | 2022-08-17 | 抗ｇｉｔｒ抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130091A Pending JP2022159476A (ja) | 2016-06-10 | 2022-08-17 | 抗ｇｉｔｒ抗体およびその使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10738126B2 (https=) |
| EP (2) | EP4344748A3 (https=) |
| JP (2) | JP7162535B2 (https=) |
| KR (1) | KR102495601B1 (https=) |
| CN (1) | CN109563170B (https=) |
| AU (1) | AU2017278193B9 (https=) |
| BR (1) | BR112018075434A2 (https=) |
| CA (1) | CA3027121A1 (https=) |
| CL (1) | CL2018003515A1 (https=) |
| CO (1) | CO2018013298A2 (https=) |
| IL (1) | IL263273B2 (https=) |
| MA (1) | MA45233A (https=) |
| MX (2) | MX2018015350A (https=) |
| MY (1) | MY200162A (https=) |
| PH (1) | PH12018502502A1 (https=) |
| SG (1) | SG11201810525XA (https=) |
| UA (1) | UA128687C2 (https=) |
| WO (1) | WO2017214548A1 (https=) |
| ZA (1) | ZA201807920B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| US10738126B2 (en) | 2016-06-10 | 2020-08-11 | Regeneron Pharmaceuticals, Inc. | Anti-GITR antibodies and uses thereof |
| SG10201912663YA (en) | 2016-10-11 | 2020-03-30 | Agenus Inc | Anti-lag-3 antibodies and methods of use thereof |
| CA3040924A1 (en) | 2016-12-09 | 2018-06-14 | Regeneron Pharmaceuticals, Inc. | Systems and methods for sequencing t cell receptors and uses thereof |
| KR102909650B1 (ko) * | 2018-03-13 | 2026-01-08 | 터스크 테라퓨틱스 리미티드 | 종양 특이적 세포 고갈에 대한 항-cd25 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020167919A1 (en) | 2019-02-12 | 2020-08-20 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for using bispecific antibodies to bind complement and a target antigen |
| RU2734432C1 (ru) | 2019-04-23 | 2020-10-16 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело, которое специфически связывается с GITR |
| WO2021136503A1 (en) * | 2020-01-02 | 2021-07-08 | Nanjing GenScript Biotech Co., Ltd. | Anti-gitr antibodies and uses thereof |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| AU2021232041A1 (en) * | 2020-03-06 | 2022-09-08 | Regeneron Pharmaceuticals, Inc. | Anti-GITR antibodies and uses thereof |
| CN116761622A (zh) * | 2021-01-08 | 2023-09-15 | 苏州丁孚靶点生物技术有限公司 | 药物产品及其用途 |
| TW202237642A (zh) * | 2021-01-08 | 2022-10-01 | 美商１０Ｘ基因組學有限公司 | 對冠狀病毒具有特異性的抗原結合多肽及其用途 |
| AU2022272117A1 (en) * | 2021-05-10 | 2024-01-04 | Medimabbio Inc. | Anti-gitr antibodies and uses thereof |
| WO2023175614A1 (en) | 2022-03-15 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| ES2308787T3 (es) | 1996-08-16 | 2008-12-01 | Schering Corporation | Antigenos de superficie de celular de mamiferos; reactivos relacionados. |
| US6503184B1 (en) | 1997-10-21 | 2003-01-07 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
| US6689607B2 (en) | 1997-10-21 | 2004-02-10 | Human Genome Sciences, Inc. | Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
| JP4485049B2 (ja) | 1997-11-18 | 2010-06-16 | ジェネンテック， インコーポレイテッド | Ｄｎａ１９３５５ポリペプチドという腫瘍壊死因子相同体 |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| EP1462114A1 (en) | 2003-03-28 | 2004-09-29 | Universiteit Utrecht Holding B.V. | Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18) |
| JP4638876B2 (ja) | 2003-05-23 | 2011-02-23 | ワイス | Ｇｉｔｒリガンド及びｇｉｔｒリガンド関連分子及び抗体及びその使用 |
| US20060099171A1 (en) | 2004-11-05 | 2006-05-11 | Masahide Tone | Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells |
| AU2006230099B2 (en) * | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| WO2007133822A1 (en) | 2006-01-19 | 2007-11-22 | Genzyme Corporation | Gitr antibodies for the treatment of cancer |
| US20100061984A1 (en) | 2006-01-20 | 2010-03-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for modulation of suppressor t cell activation |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| ES2776406T3 (es) | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| EP2473531A4 (en) | 2009-09-03 | 2013-05-01 | Merck Sharp & Dohme | Anti-gitr antibodies |
| US20130108641A1 (en) | 2011-09-14 | 2013-05-02 | Sanofi | Anti-gitr antibodies |
| WO2013051718A1 (ja) | 2011-10-07 | 2013-04-11 | 国立大学法人三重大学 | キメラ抗原受容体 |
| KR101566539B1 (ko) | 2012-06-08 | 2015-11-05 | 국립암센터 | 신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도 |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| TW201605896A (zh) * | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| SG10201912986PA (en) | 2014-05-28 | 2020-02-27 | Agenus Inc | Anti-gitr antibodies and methods of use thereof |
| PT3151921T (pt) | 2014-06-06 | 2019-11-21 | Bristol Myers Squibb Co | Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos |
| JP2017531427A (ja) | 2014-10-03 | 2017-10-26 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）抗体およびその使用法 |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| WO2016070051A2 (en) * | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| US10738126B2 (en) | 2016-06-10 | 2020-08-11 | Regeneron Pharmaceuticals, Inc. | Anti-GITR antibodies and uses thereof |
-
2017
- 2017-06-09 US US15/619,068 patent/US10738126B2/en active Active
- 2017-06-09 UA UAA201811485A patent/UA128687C2/uk unknown
- 2017-06-09 MY MYPI2018002044A patent/MY200162A/en unknown
- 2017-06-09 CN CN201780048899.6A patent/CN109563170B/zh active Active
- 2017-06-09 EP EP23214299.2A patent/EP4344748A3/en not_active Withdrawn
- 2017-06-09 AU AU2017278193A patent/AU2017278193B9/en active Active
- 2017-06-09 KR KR1020187036000A patent/KR102495601B1/ko active Active
- 2017-06-09 EP EP17731435.8A patent/EP3468999B1/en active Active
- 2017-06-09 MX MX2018015350A patent/MX2018015350A/es unknown
- 2017-06-09 JP JP2018562357A patent/JP7162535B2/ja active Active
- 2017-06-09 IL IL263273A patent/IL263273B2/en unknown
- 2017-06-09 SG SG11201810525XA patent/SG11201810525XA/en unknown
- 2017-06-09 CA CA3027121A patent/CA3027121A1/en active Pending
- 2017-06-09 MA MA045233A patent/MA45233A/fr unknown
- 2017-06-09 WO PCT/US2017/036818 patent/WO2017214548A1/en not_active Ceased
- 2017-06-09 BR BR112018075434-0A patent/BR112018075434A2/pt not_active Application Discontinuation
-
2018
- 2018-11-22 ZA ZA2018/07920A patent/ZA201807920B/en unknown
- 2018-11-27 PH PH12018502502A patent/PH12018502502A1/en unknown
- 2018-12-07 CL CL2018003515A patent/CL2018003515A1/es unknown
- 2018-12-07 CO CONC2018/0013298A patent/CO2018013298A2/es unknown
- 2018-12-10 MX MX2022014695A patent/MX2022014695A/es unknown
-
2020
- 2020-06-26 US US16/913,963 patent/US11414494B2/en active Active
-
2022
- 2022-07-13 US US17/812,256 patent/US20230042324A1/en not_active Abandoned
- 2022-08-17 JP JP2022130091A patent/JP2022159476A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521098A5 (https=) | ||
| KR102713223B1 (ko) | 항-pd-l1 항체 | |
| JP6839772B2 (ja) | 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体 | |
| JP6701213B2 (ja) | 抗ｐｄ−１抗体 | |
| JP2021527431A5 (https=) | ||
| JP6518005B2 (ja) | Ｐｄ−ｌ１抗体 | |
| WO2020102501A1 (en) | Anti-nkg2a antibodies and uses thereof | |
| JP2021531764A5 (https=) | ||
| JP2019521645A5 (https=) | ||
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| JP2017535257A5 (https=) | ||
| RU2019134352A (ru) | Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap | |
| JP2017532037A5 (https=) | ||
| JP2019500892A5 (https=) | ||
| JP2020515247A5 (https=) | ||
| AU2020283817A1 (en) | TIGIT and PD-1/TIGIT-binding molecules | |
| JP2019500891A5 (https=) | ||
| JPWO2019246514A5 (https=) | ||
| KR20160113272A (ko) | Tim-3에 대한 항체 분자 및 그의 용도 | |
| JP2018501197A5 (https=) | ||
| IL299348B2 (en) | Antigen-binding proteins against human papillomavirus and methods of using them | |
| WO2019030377A1 (en) | CD96 BINDING AGENTS AS IMMUNOMODULATORS | |
| JP2020504078A5 (https=) | ||
| JP2019528046A5 (https=) | ||
| JP2023517794A (ja) | 抗ｔｎｆｒ２抗体及びその使用 |